Key Highlights
- Johnson & Johnson MedTech to acquire V-Wave Ltd. for $600M upfront.
- Potential milestone payments could reach up to $1.1 billion.
- Acquisition enhances Johnson & Johnson’s cardiovascular disease treatment portfolio.
- V-Wave’s Ventura® Interatrial Shunt targets heart failure with reduced ejection fraction (HFrEF).
Source: Business Wire
Notable Quotes
- “We are excited to welcome V-Wave to Johnson & Johnson MedTech and to take another meaningful step toward transforming the standard of care for cardiovascular disease.” — Tim Schmid, Executive Vice President and Worldwide Chairman at Johnson & Johnson MedTech
- “We are confident that Johnson & Johnson MedTech is well-positioned to ensure V-Wave’s breakthrough ideas and technology reach patients in need as quickly and effectively as possible.” — Dr. Neal Eigler, Chief Executive Officer at V-Wave
SoHC's Take
Johnson & Johnson’s strategic acquisition of V-Wave Ltd. marks a significant expansion of its MedTech division, particularly in the treatment of heart failure. The Ventura® Interatrial Shunt, with its FDA Breakthrough Device Designation, positions Johnson & Johnson at the forefront of innovative, minimally invasive cardiovascular solutions. This move underscores the company’s commitment to addressing the global burden of heart failure, a condition with high unmet needs and significant growth potential. The acquisition aligns with Johnson & Johnson’s broader strategy of investing in high-growth, high-impact medical technologies.
